162 related articles for article (PubMed ID: 32854385)
21. Cutaneously applied 4-hydroxytamoxifen is not carcinogenic in female rats.
Sauvez F; Drouin DS; Attia M; Bertheux H; Forster R
Carcinogenesis; 1999 May; 20(5):843-50. PubMed ID: 10334202
[TBL] [Abstract][Full Text] [Related]
22. Effect of permeation enhancers on the penetration mechanism of transfersomal gel of ketoconazole.
Rajan R; Vasudevan DT
J Adv Pharm Technol Res; 2012 Apr; 3(2):112-6. PubMed ID: 22837959
[TBL] [Abstract][Full Text] [Related]
23. Ultra-high performance liquid chromatography tandem mass spectrometric method for the determination of tamoxifen, N-desmethyltamoxifen, 4-hydroxytamoxifen and endoxifen in dried blood spots--development, validation and clinical application during breast cancer adjuvant therapy.
Antunes MV; Raymundo S; de Oliveira V; Staudt DE; Gössling G; Peteffi GP; Biazús JV; Cavalheiro JA; Tre-Hardy M; Capron A; Haufroid V; Wallemacq P; Schwartsmann G; Linden R
Talanta; 2015 Jan; 132():775-84. PubMed ID: 25476377
[TBL] [Abstract][Full Text] [Related]
24. Selenium disrupts estrogen receptor (alpha) signaling and potentiates tamoxifen antagonism in endometrial cancer cells and tamoxifen-resistant breast cancer cells.
Shah YM; Al-Dhaheri M; Dong Y; Ip C; Jones FE; Rowan BG
Mol Cancer Ther; 2005 Aug; 4(8):1239-49. PubMed ID: 16093440
[TBL] [Abstract][Full Text] [Related]
25. Vaginal tamoxifen for treatment of vulvar and vaginal atrophy: Pharmacokinetics and local tolerance in a rabbit model over 28 days.
Chollet J; Mermelstein F; Rocamboli SC; Friend DR
Int J Pharm; 2019 Oct; 570():118691. PubMed ID: 31518632
[TBL] [Abstract][Full Text] [Related]
26. Postoperative tamoxifen for ductal carcinoma in situ.
Staley H; McCallum I; Bruce J
Cochrane Database Syst Rev; 2012 Oct; 10():CD007847. PubMed ID: 23076938
[TBL] [Abstract][Full Text] [Related]
27. Development of a high-performance liquid chromatography method with fluorescence detection for the routine quantification of tamoxifen, endoxifen and 4-hydroxytamoxifen in plasma from breast cancer patients.
Rangel-Méndez JA; Graniel-Sabido MJ; Sánchez-Cruz JF; Moo-Puc R
Biomed Chromatogr; 2019 Apr; 33(4):e4462. PubMed ID: 30536934
[TBL] [Abstract][Full Text] [Related]
28. Tamoxifen added to radiotherapy and surgery for the treatment of ductal carcinoma in situ of the breast: a meta-analysis of 2 randomized trials.
Petrelli F; Barni S
Radiother Oncol; 2011 Aug; 100(2):195-9. PubMed ID: 21411161
[TBL] [Abstract][Full Text] [Related]
29. Emu oil based nano-emulgel for topical delivery of curcumin.
Jeengar MK; Rompicharla SV; Shrivastava S; Chella N; Shastri NR; Naidu VG; Sistla R
Int J Pharm; 2016 Jun; 506(1-2):222-36. PubMed ID: 27109049
[TBL] [Abstract][Full Text] [Related]
30. EM-652 (SCH 57068), a third generation SERM acting as pure antiestrogen in the mammary gland and endometrium.
Labrie F; Labrie C; Bélanger A; Simard J; Gauthier S; Luu-The V; Mérand Y; Giguere V; Candas B; Luo S; Martel C; Singh SM; Fournier M; Coquet A; Richard V; Charbonneau R; Charpenet G; Tremblay A; Tremblay G; Cusan L; Veilleux R
J Steroid Biochem Mol Biol; 1999; 69(1-6):51-84. PubMed ID: 10418981
[TBL] [Abstract][Full Text] [Related]
31. BreastDefend enhances effect of tamoxifen in estrogen receptor-positive human breast cancer in vitro and in vivo.
Cheng S; Castillo V; Welty M; Alvarado M; Eliaz I; Temm CJ; Sandusky GE; Sliva D
BMC Complement Altern Med; 2017 Feb; 17(1):115. PubMed ID: 28209156
[TBL] [Abstract][Full Text] [Related]
32. Comparative binding affinities of tamoxifen, 4-hydroxytamoxifen, and desmethyltamoxifen for estrogen receptors isolated from human breast carcinoma: correlation with blood levels in patients with metastatic breast cancer.
Fabian C; Tilzer L; Sternson L
Biopharm Drug Dispos; 1981; 2(4):381-90. PubMed ID: 7317574
[TBL] [Abstract][Full Text] [Related]
33. 4-Hydroxylated metabolites of the antiestrogens tamoxifen and toremifene are metabolized to unusually stable quinone methides.
Fan PW; Zhang F; Bolton JL
Chem Res Toxicol; 2000 Jan; 13(1):45-52. PubMed ID: 10649966
[TBL] [Abstract][Full Text] [Related]
34. Effects of morin on the bioavailability of tamoxifen and its main metabolite, 4-hydroxytamoxifen, in rats.
Shin SC; Piao YJ; Choi JS
In Vivo; 2008; 22(3):391-5. PubMed ID: 18610753
[TBL] [Abstract][Full Text] [Related]
35. Awareness of preventive medication among women at high risk for breast cancer and their willingness to consider transdermal or oral tamoxifen: a focus group study.
Karavites LC; Allu S; Khan SA; Kaiser K
BMC Cancer; 2015 Nov; 15():878. PubMed ID: 26552376
[TBL] [Abstract][Full Text] [Related]
36. Initiation of and adherence to tamoxifen and aromatase inhibitor therapy among elderly women with ductal carcinoma in situ.
Zhao H; Hei N; Wu Y; Chan W; Lei X; Cameron C; Chang S; Chavez-MacGregor M; Giordano SH
Cancer; 2017 May; 123(6):940-947. PubMed ID: 27780311
[TBL] [Abstract][Full Text] [Related]
37. Mutations induced by alpha-hydroxytamoxifen in the lacI and cII genes of Big Blue transgenic rats.
Chen T; Gamboa da Costa G; Marques MM; Shelton SD; Beland FA; Manjanatha MG
Carcinogenesis; 2002 Oct; 23(10):1751-7. PubMed ID: 12376486
[TBL] [Abstract][Full Text] [Related]
38. Effects of epigallocatechin gallate on the oral bioavailability and pharmacokinetics of tamoxifen and its main metabolite, 4-hydroxytamoxifen, in rats.
Shin SC; Choi JS
Anticancer Drugs; 2009 Aug; 20(7):584-8. PubMed ID: 19491656
[TBL] [Abstract][Full Text] [Related]
39. Boron-Based 4-Hydroxytamoxifen Bioisosteres for Treatment of de Novo Tamoxifen Resistant Breast Cancer.
Jiang Q; Zhong Q; Zhang Q; Zheng S; Wang G
ACS Med Chem Lett; 2012 Apr; 3(5):392-396. PubMed ID: 23864928
[TBL] [Abstract][Full Text] [Related]
40. Activation of tamoxifen and its metabolite alpha-hydroxytamoxifen to DNA-binding products: comparisons between human, rat and mouse hepatocytes.
Phillips DH; Carmichael PL; Hewer A; Cole KJ; Hardcastle IR; Poon GK; Keogh A; Strain AJ
Carcinogenesis; 1996 Jan; 17(1):89-94. PubMed ID: 8565142
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
